Andrew has two decades of experience in the pharmaceutical industry, spanning from preclinical development, through early clinical formulation development into late stage development, scale up and commercialisation. Andrew has a particular interest in enabling technologies for bioavailability enhancement, characterisation of all delivery formats, innovate technologies and understanding drug product structure – drug product function relationships. Andrew’s focus at Quotient Sciences is in Translation Pharmaceutics and the acceleration in candidate progression and associated benefits provided by tighter integration of formulation development, clinical drug product manufacture and clinical dosing. Prior to Quotient Sciences, Andrew worked at Cooper Surgical and Healthcare as a Program Director and at Catalent as an Open Innovation Director covering two business units. Prior to this, Andrew spent 15 years at Juniper Pharma Services and Molecular Profiles CDMO’s in a variety roles combining technical and commercial knowledge, sitting at the operational and business interfaces with external clients. Andrew holds a BSc, MSc and PhD in physical chemistry from the University of Bristol.